Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

152 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy, patient-reported outcomes, and safety of the anti-granulocyte macrophage colony-stimulating factor antibody otilimab (GSK3196165) in patients with rheumatoid arthritis: a randomised, phase 2b, dose-ranging study.
Buckley CD, Simón-Campos JA, Zhdan V, Becker B, Davy K, Fisheleva E, Gupta A, Hawkes C, Inman D, Layton M, Mitchell N, Patel J, Saurigny D, Williamson R, Tak PP. Buckley CD, et al. Among authors: davy k. Lancet Rheumatol. 2020 Nov;2(11):e677-e688. doi: 10.1016/S2665-9913(20)30229-0. Epub 2020 Oct 7. Lancet Rheumatol. 2020. PMID: 38279364
Anti-granulocyte-macrophage colony-stimulating factor antibody otilimab in patients with hand osteoarthritis: a phase 2a randomised trial.
Schett G, Bainbridge C, Berkowitz M, Davy K, Fernandes S, Griep E, Harrison S, Gupta A, Lloyd-Hughes J, Roberts A, Layton M, Nowak NA, Patel J, Rech J, Smith JE, Watts S, Tak PP. Schett G, et al. Among authors: davy k. Lancet Rheumatol. 2020 Oct;2(10):e623-e632. doi: 10.1016/S2665-9913(20)30171-5. Epub 2020 Sep 23. Lancet Rheumatol. 2020. PMID: 38273625
MRI of the joint and evaluation of the granulocyte-macrophage colony-stimulating factor-CCL17 axis in patients with rheumatoid arthritis receiving otilimab: a phase 2a randomised mechanistic study.
Genovese MC, Berkowitz M, Conaghan PG, Peterfy C, Davy K, Fisheleva E, Gupta A, Inman D, Janiczek R, Layton M, Mitchell N, Patel J, Roberts A, Saurigny D, Smith JE, Williamson R, Tak PP. Genovese MC, et al. Among authors: davy k. Lancet Rheumatol. 2020 Nov;2(11):e666-e676. doi: 10.1016/S2665-9913(20)30224-1. Epub 2020 Oct 7. Lancet Rheumatol. 2020. PMID: 38279363
Targeting GM-CSF in rheumatological conditions: risk of PAP - Authors' reply.
Genovese MC, Buckley CD, Saurigny D, Schett G, Davy K, Gupta A, Smith JE, Patel J, Tak PP. Genovese MC, et al. Among authors: davy k. Lancet Rheumatol. 2021 Jul;3(7):e473-e474. doi: 10.1016/S2665-9913(21)00146-6. Lancet Rheumatol. 2021. PMID: 38279397 No abstract available.
A randomised trial of anti-GM-CSF otilimab in severe COVID-19 pneumonia (OSCAR).
Patel J, Bass D, Beishuizen A, Bocca Ruiz X, Boughanmi H, Cahn A, Colombo H, Criner GJ, Davy K, de-Miguel-Díez J, Doreski PA, Fernandes S, François B, Gupta A, Hanrott K, Hatlen T, Inman D, Isaacs JD, Jarvis E, Kostina N, Kropotina T, Lacherade JC, Lakshminarayanan D, Martinez-Ayala P, McEvoy C, Meziani F, Monchi M, Mukherjee S, Muñoz-Bermúdez R, Neisen J, O'Shea C, Plantefeve G, Schifano L, Schwab LE, Shahid Z, Shirano M, Smith JE, Sprinz E, Summers C, Terzi N, Tidswell MA, Trefilova Y, Williamson R, Wyncoll D, Layton M. Patel J, et al. Among authors: davy k. Eur Respir J. 2023 Feb 2;61(2):2101870. doi: 10.1183/13993003.01870-2021. Print 2023 Feb. Eur Respir J. 2023. PMID: 36229048 Free PMC article. Clinical Trial.
Association of Minimal Residual Disease Negativity Rates With Progression Free Survival in Frontline Therapy Trials for Newly Diagnosed Multiple Myeloma: A Meta-analysis.
Ficek J, Kalaitzaki E, Yuan SS, Tosolini A, Du L, Kremer BE, Davy K, Zhou H, Chen TT. Ficek J, et al. Among authors: davy k. Clin Lymphoma Myeloma Leuk. 2023 May;23(5):e213-e221. doi: 10.1016/j.clml.2023.02.005. Epub 2023 Feb 21. Clin Lymphoma Myeloma Leuk. 2023. PMID: 36907767 Review.
Association of HIV and HCV Infection With Carotid Artery Plaque Echomorphology in the MACS/WIHS Combined Cohort Study.
Bravo CA, Moon JY, Davy K, Kaplan RC, Anastos K, Rodriguez CJ, Post WS, Gange SJ, Kassaye SG, Kingsley LA, Lazar JM, Mack WJ, Pyslar N, Tien PC, Witt MD, Palella FJ, Li Y, Yan M, Hodis HN, Hanna DB. Bravo CA, et al. Among authors: davy k. Stroke. 2024 Mar;55(3):651-659. doi: 10.1161/STROKEAHA.123.043922. Epub 2024 Feb 9. Stroke. 2024. PMID: 38333992
Ultra-processed food intake, gut microbiome, and glucose homeostasis in mid-life adults: Background, design, and methods of a controlled feeding trial.
Capra BT, Hudson S, Helder M, Laskaridou E, Johnson AL, Gilmore C, Marinik E, Hedrick VE, Savla J, David LA, Davy KP, Davy BM. Capra BT, et al. Among authors: davy kp. Contemp Clin Trials. 2024 Feb;137:107427. doi: 10.1016/j.cct.2024.107427. Epub 2024 Jan 4. Contemp Clin Trials. 2024. PMID: 38184104 Free PMC article.
The influence of ultra-processed food consumption on reward processing and energy intake: Background, design, and methods of a controlled feeding trial in adolescents and young adults.
Rego MLM, Leslie E, Capra BT, Helder M, Yu W, Katz B, Davy KP, Hedrick VE, Davy BM, DiFeliceantonio AG. Rego MLM, et al. Among authors: davy kp. Contemp Clin Trials. 2023 Dec;135:107381. doi: 10.1016/j.cct.2023.107381. Epub 2023 Nov 5. Contemp Clin Trials. 2023. PMID: 37935307 Free article. Clinical Trial.
152 results